the-lancet-oncology

The Lancet Oncology (the-lancet-oncology)

Journal positioning

The Lancet Oncology is a flagship specialty title in the Lancet family and one of the world's most prestigious clinical oncology journals, published by Elsevier. It publishes practice-changing cancer clinical trials, oncology policy, cancer epidemiology, and translational cancer research that is directly relevant to the clinical management of cancer at a global level. The journal maintains the Lancet family's editorial standards: rigorous trial registration, CONSORT compliance, equity and global-health consciousness, and a bias toward findings that shift oncology practice or inform cancer policy. Studies that are methodologically sound but incremental—small improvements in surrogate endpoints, single-arm studies without historical context, or descriptive epidemiology without actionable implications—are unlikely to succeed here.

This skill is a fit / venue-selection / re-framing tool. It does not replace the journal's current official submission guidelines. Before submitting, re-check the live author instructions on the Lancet/Elsevier site or submission system.

When to trigger

• The author names The Lancet Oncology as the target venue for a phase III cancer trial, cancer epidemiology analysis, or oncology-policy paper.
• A cancer clinical trial has results that could change standard of care across a patient population at international scale.
• A cancer-burden or cancer-control analysis has policy implications for global or regional oncology systems.
• The author needs The Lancet Oncology's desk-reject risks and credible alternatives before submitting.

Scope & topic fit

• Phase III and large phase II randomised controlled trials in any cancer type with patient-centred primary endpoints (overall survival, progression-free survival with mature data, quality of life).
• First-in-class drug approvals, definitive biomarker-selected trial results, and adaptive or platform trial designs with practice-changing results.
• Cancer epidemiology: global cancer burden, incidence and mortality trends, population-level cancer screening effectiveness.
• Oncology policy and health-systems research: cancer control in LMICs, access to cancer medicines, treatment guidelines at population scale.
• Precision oncology: biomarker-defined patient populations, molecular tumour boards, genomic stratification with clinical outcome data.
• Translational findings from trials: correlative biomarker data within a practice-changing clinical trial, not standalone discovery.

Method & evidence bar

• Randomised trials must be pre-registered (ClinicalTrials.gov or ISRCTN or equivalent), CONSORT-compliant in full including a CONSORT flow diagram, and powered for a clinically meaningful primary endpoint.
• Phase II single-arm studies are published only when they establish a new standard for a rare tumour type or a breakthrough clinical signal with regulatory-approval implication.
• Systematic reviews and meta-analyses of cancer trials require PRISMA adherence, PROSPERO registration, and GRADE evidence profiling.
• Survival analyses must report hazard ratios with confidence intervals, Kaplan-Meier curves with patients-at-risk tables, and median follow-up duration.
• Biomarker and molecular analyses embedded within trials must follow pre-specified analysis plans; exploratory correlative data should be clearly labelled as hypothesis-generating.
• Ethics approval, independent data-safety monitoring board (for phase III trials), and informed consent are mandatory; ICMJE authorship and competing-interests disclosure are required.

Structure & house style

• The Lancet Oncology uses a structured abstract (background, methods, findings, interpretation) followed by a funding statement; the Interpretation sentence must state the clinical implication directly.
• An "Added value of this study" summary panel (what is already known, what this study adds) is required; it must be specific to this trial's contribution—generic claims are rejected.
• Opening paragraphs should establish the unmet clinical need and the current standard of care that this study addresses or surpasses.
• Kaplan-Meier figures are standard; ensure they include patients-at-risk tables; colour-blind-accessible palettes are expected.
• Statistical reporting must include absolute differences in survival rates at landmark timepoints in addition to hazard ratios; minimise sole reliance on relative-effect measures.
• Ancillary oncology-specific content: subgroup forest plots must note that subgroup analyses are exploratory unless pre-specified.

Official-submission checklist

• Before giving submission-ready advice, read ../../resources/source-basis.md and ../../resources/official-source-map.md; start from the official source anchors for this journal family, then cite the current journal-specific page you checked.
• Search the live site for "The Lancet Oncology information for authors" and follow the current Elsevier/Lancet version.
• Re-check article type, current word/abstract/figure limits, and the "Added value" panel format.
• Confirm trial registration number, ethics approval reference, independent data-safety monitoring board statement (phase III), and informed consent are documented.
• Submit CONSORT checklist (or PRISMA for reviews) as a supplementary file with page-number citations.
• Re-check data-sharing statement: what IPD or summary data will be shared, when, via which platform, and under what access conditions.
• Re-check competing-interests declaration, funding disclosure (industry vs. academic funding independence), ICMJE author-contribution statement, and AI-use disclosure.
• Re-check open-access/APC and licensing options; preprint policy.
• If the live official instructions conflict with this skill, the official instructions win.

Pre-submission self-check

• One sentence stating which current standard-of-care this study supersedes or complements, and for which patient population.
• The CONSORT flow diagram is prepared; patients at risk are shown in survival curves; hazard ratios and landmark survival rates are both reported.
• The "Added value" panel is specific: what existing evidence was incomplete and what this study conclusively establishes.
• Biomarker or subgroup analyses are clearly labelled as pre-specified or exploratory.
• Trial registration, ethics, and data-sharing statement are complete.
• All competing interests (especially industry support) are fully declared with clear statement of sponsor role in design, analysis, and publication.

Common desk-reject triggers

• Phase II single-arm trial in a common tumour type without a compelling unmet-need or breakthrough-designation rationale.
• CONSORT flow diagram missing; primary endpoint differs from the registered endpoint without transparent amendment explanation.
• Survival analyses without patients-at-risk tables or with immature follow-up that prevents meaningful interpretation.
• Competing-interests disclosure that is incomplete or where the sponsor conducted the primary statistical analysis with no independent verification.
• "Added value" panel that is generic or repeats the abstract rather than specifying what this study adds relative to existing evidence.
• Biomarker or translational paper without a clinical trial anchor—purely preclinical or discovery studies belong in disease-biology journals.

Re-routing decision

• Same trial but more broadly generalised to all medicine beyond oncology → the-lancet.
• ASCO-sponsored or US-focused oncology trial seeking society-journal publication → journal-of-clinical-oncology.
• Mechanistic cancer-biology study underlying the clinical finding → cancer-cell or nature-medicine.
• Phase I/II with strong translational mechanism → nature-medicine or cancer-discovery.
• Rare haematological malignancy with mechanistic depth → blood.

Output format

[Fit] High / Medium / Low (one-line reason)
[Target] The Lancet Oncology
[Topic tags] <2–3 closest topics>
[Method/evidence] <does registration / CONSORT / primary endpoint / practice-change scope clear the Lancet Oncology bar?>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type/length / structured abstract / Added-value panel / CONSORT checklist / survival figures / data sharing / ethics / disclosure>
[Re-route suggestion] <if not a fit, a better-matched venue>